David Sallman, MD, on Updates From the AMELI-01 Trial of UCART123v1.2 for AML

Video

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

“We had 2 patients that had a clinical benefit, 1 had a blast reduction from 60% to 5% and was able to get a donor lymphocyte infusion. The other was quite remarkable and was a personal patient of mine who had high blasts, had a relapse post-transplant and had failed many lines of therapy with horrendous grade 4 cytopenia. She was treated in AMELI-01 and achieved MRD negative complete remission [CR] by the end of the first month and she's now been in a durable MRD negative CR for 1 year without any subsequent therapy, including second transplant or donor lymphocyte infusion. It’s 1 of the most remarkable responses of CAR T in patients with acute myeloid leukemia that I’ve seen.”

UCART123v1.2, in combination with an alemtuzumab plus fludarabine and cyclophosphamide lymphodepleting regimen to improve cell expansion and persistence had a manageable safety profile and yielded responses in patients with acute myeloid leukemia (AML). Data from the AMELI-01 clinical trial (NCT04106076) evaluating the allogeneic chimeric antigen receptor (CAR) T-cell therapy were presented by David Sallman, MD, assistant member, department of malignant hematology, Moffitt Cancer Center at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.

CGTLive spoke with Sallman to learn more about the updated data from the trial, including 2 cases of complete remissions. He also discussed working to manage the ongoing challenges with cytokine release syndrome in CAR T-treated patients and next steps for the trial.

REFERENCE
Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML). Presented atL 64th ASH Annual Meeting, December 10-12, New Orleans, Louisiana. Abstract #981

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.